More about

Advanced Gastroesophageal Adenocarcinoma

News
January 27, 2025
1 min read
Save

Combination does not extend survival vs. chemotherapy in gastroesophageal cancer

Combination does not extend survival vs. chemotherapy in gastroesophageal cancer

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced gastroesophageal adenocarcinoma, according to the agents’ manufacturers.